These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 31991479)
21. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study. Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519 [TBL] [Abstract][Full Text] [Related]
22. [Chronic Lymphocytic Leukemia. New targeted therapy option Ibrutinib]. Bruhn C Med Monatsschr Pharm; 2014 Jul; 37(7):268-9. PubMed ID: 25065170 [No Abstract] [Full Text] [Related]
23. Ibrutinib for Chronic Lymphocytic Leukemia. Ruchlemer R; Ben Ami R; Lachish T N Engl J Med; 2016 Apr; 374(16):1593-4. PubMed ID: 27096597 [No Abstract] [Full Text] [Related]
24. Ibrutinib for Chronic Lymphocytic Leukemia. Rigolin GM; Cavazzini F; Cuneo A N Engl J Med; 2016 Apr; 374(16):1593. PubMed ID: 27096596 [No Abstract] [Full Text] [Related]
31. Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program. Hillmen P; Diels J; Healy N; Iraqi W; Aschan J; Wildgust M Haematologica; 2018 May; 103(5):e204-e206. PubMed ID: 29419428 [No Abstract] [Full Text] [Related]
32. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603 [TBL] [Abstract][Full Text] [Related]
33. Ibrutinib (Imbruvica) for chronic lymphocytic leukemia. Med Lett Drugs Ther; 2014 Apr; 56(1440):29-30. PubMed ID: 24736247 [No Abstract] [Full Text] [Related]
34. Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib. England JT; Leitch HA Leuk Lymphoma; 2018 Mar; 59(3):752-754. PubMed ID: 28728450 [No Abstract] [Full Text] [Related]
35. Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia. Skrabs C; Pickl WF; Perkmann T; Jäger U; Gessl A J Clin Pharm Ther; 2018 Feb; 43(1):145-149. PubMed ID: 28753229 [TBL] [Abstract][Full Text] [Related]
36. Ibrutinib increased survival more than chlorambucil in older patients with untreated chronic lymphocytic leukemia. Aronson FR Ann Intern Med; 2016 Apr; 164(8):JC44. PubMed ID: 27089094 [No Abstract] [Full Text] [Related]
37. Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib. Boudin L; Patient M; Tsitsi Nding Tsogou P; Roméo E; Bladé JS; de Jauréguiberry JP Bull Cancer; 2019 Jan; 106(1):84-85. PubMed ID: 30579570 [No Abstract] [Full Text] [Related]
38. Management of hypogammaglobulinemia and recurrent infections in a chronic lymphocytic leukemia patient receiving ibrutinib. Jiang F; Verma P Ann Allergy Asthma Immunol; 2018 Mar; 120(3):324-325. PubMed ID: 29174859 [No Abstract] [Full Text] [Related]
39. Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib. Christoforidou A; Kapsas G; Bezirgiannidou Z; Papamichos S; Kotsianidis Ι Turk J Haematol; 2018 May; 35(2):147-149. PubMed ID: 29391330 [No Abstract] [Full Text] [Related]
40. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Michallet AS; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; de Guibert S; Orsini F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Lévy V; Nguyen-Khac F; Le Garff-Tavernier M; Aanei C; Ticchioni M; Letestu R; Feugier P Lancet Haematol; 2019 Sep; 6(9):e470-e479. PubMed ID: 31324600 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]